Plain-English translation of NCT04409431 on ClinicalTrials.gov ↗ · Source last updated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial compares two ways to treat primary aldosteronism, a condition where one or both adrenal glands produce too much of a hormone called aldosterone, causing hard-to-control high blood pressure. You would either receive a minimally invasive procedure called adrenal artery ablation (where doctors use a catheter to deliver alcohol to reduce the overactive gland) or take spironolactone, a medication that blocks aldosterone's effects. The study will track how well each approach lowers blood pressure and protects your heart over time.
Most patients with primary aldosteronism cannot have surgery to remove the problem gland, so they rely on long-term medication that can cause unwanted side effects like high potassium levels and breast tissue growth. Researchers want to know if the new ablation procedure can lower aldosterone levels and protect the heart without these medication side effects.
If accepted into this study, you would be randomly assigned to one of two groups: either the adrenal artery ablation procedure (a catheter-based treatment performed in a hospital setting) or daily spironolactone medication taken by mouth. Throughout the study, you would have regular visits to check your blood pressure, blood tests to measure electrolytes and kidney function, heart imaging to assess cardiovascular health, and follow-up assessments to track long-term outcomes and any side effects.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
China